Due to multidrug-resistant strains, shigellosis has become difficult to treat. Shigella4V (S4V) is a tetravalent bioconjugate vaccine candidate that includes O-antigen-polysaccharides of the most ...
has granted Fast Track designation to Shigella4V (S4V), the world’s most clinically advanced tetravalent bioconjugate shigellosis vaccine candidate, for which Valneva obtained an exclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback